Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Carcinoma, Ovarian Epithelial 3Melanoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Platinum-resistant Recurrent Ovarian Cancer 1Peritoneal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Cisplatin 7Oxaliplatin 5Paclitaxel 4Fluorouracil 4Carboplatin 4Albumin-Bound Paclitaxel 4Taxes 3Mitomycin 3130-nm albumin-bound paclitaxel 3Nivolumab 2Leucovorin 2Doxorubicin 2veliparib 1tremelimumab 1talimogene laherparepvec 1soluble LAG-3 protein, human 1sodium thiosulfate 1pembrolizumab 1nintedanib 1irinotecan sucrosofate 1durvalumab 1dehydroftorafur 1cc-486 1avelumab 1Trastuzumab 1Semaxinib 1Radiotherapy 1Radiation 1Platinum 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Peritoneal Neoplasms × 1-dodecylpyridoxal × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡